ABOUT CORIOLIS PHARMA
Coriolis Pharma is a globally operating, science-driven Contract Research and Development Organization (CRDO). We provide integrated services in drug product development, analytical testing, and manufacturing support for liquid, frozen-liquid, and lyophilized drug products across all stages—from early development through commercialization and lifecycle management.
Our core expertise includes formulation development and analytical services delivered under both R&D and GMP conditions. Industry-experienced scientists design and execute platform and custom services for a broad range of biopharmaceutical modalities, including biologics, cell and gene therapies, and vaccines. We operate state-of-the-art laboratories in Martinsried, Germany and Durham, NC, USA and maintain a presence across Europe and the United States. Our services cover drug product development, analytical testing, and manufacturing support, with dedicated local project management enabling close collaboration and efficient communication throughout the project lifecycle.
FEATURED WEBINARS
-
![Coriolis Pharma Capabilities Update October 2026: Large Molecule]( "Coriolis Pharma Capabilities Update October 2026: Large Molecule")
Coriolis Pharma Capabilities Update October 2026: Large MoleculeIntegrated drug product development helps biopharma teams identify risks early, optimize formulation and manufacturing, and create stable, scalable biologics ready for clinical and commercial success.
-
![Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics]( "Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics")
Formulating The Future: A Practical Guide To Nucleic Acid TherapeuticsAn expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.
-
![The Road To Success]( "Drug Product Development: Preclinical To Commercial")
Drug Product Development: Preclinical To CommercialWatch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.
-
![Shedding Light On Surfactants Used As Excipient For Biologics]( "Understanding Surfactant Excipients In Biologic Formulations")
Understanding Surfactant Excipients In Biologic FormulationsUncover surfactant characterization, polysorbate degradation, and advanced analytics, such as multidimensional LC, to strengthen stability assessment and formulation for biologics and advanced therapies.
-
![Subvisible Particle Analysis]( "Subvisible Particle Analysis For End‑To‑End Quality")
Subvisible Particle Analysis For End‑To‑End QualitySee strategies for precise subvisible particle analysis, covering regulatory expectations, method validation, and controlling variability when transitioning workflows from R&D to GMP environments.
FEATURED ARTICLES
-
![Meeting, team, medical case review, treatment plan, research-GettyImages-2265129844]( "In Silico Development: What CMC Teams Can Decide Before The Lab")
In Silico Development: What CMC Teams Can Decide Before The LabFormulation risk is often a timing problem rather than a technical one. Sequence-based prediction can narrow candidates, pH, and excipient choices before scarce drug substance is committed.
-
![GettyImages-1767170794-GLP-1-peptide-chain]( "Bridging Discovery, Developability, And Commercial Reality")
Bridging Discovery, Developability, And Commercial RealityDriven by metabolic and oncology successes, the expanding peptide therapeutics market faces critical challenges requiring early, customized drug product development, stability, and safety strategies.
-
![GettyImages-1002000796-lab-research-scientist-development]( "Advancing Biologic Drug Products With Integrated Development And Analytical Services At CPHI Worldwide")
Advancing Biologic Drug Products With Integrated Development And Analytical Services At CPHI WorldwideExplore how integrated formulation, analytical, predictive, and GMP testing capabilities can help complex biologics advance toward robust manufacturing, regulatory readiness, and more.
-
![cmo-biologics-GettyImages-1327624070]( "What To Get Right Early In Subcutaneous Biologics Development")
What To Get Right Early In Subcutaneous Biologics DevelopmentHigh-concentration biologics can face viscosity and aggregation challenges. Early modeling and targeted testing optimize formulations for stability, manufacturability, and delivery.
-
![GettyImages-1432665190-pharma-manufacturing-tubes-connectors]( "When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both Matter")
When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both MatterUnderstanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.
CONTACT INFORMATION
Coriolis Pharma
Fraunhoferstraße 18b
Martinsried/Munich, 82152
GERMANY
Contact: https://www.coriolis-pharma.com/contact/
U.S. FACILITIES
BROCHURES
-
![GettyImages-2213157127-drug-formulation-discovery-pipette-liquid-vial]( "From Sequence To Clinic: Faster Decisions Through In Silico Insights")
In‑silico modeling enables early prediction of molecule stability, formulatability, and risks, reducing lab work, guiding candidate selection, and supporting efficient drug‑product development from sequence to clinic.
-
![GettyImages-1128195910-vial-white-powder-lyophilization]( "Advancing Lyophilization Through Formulation, Process Development")
Lyophilization development and modeling improve stability, streamline freeze‑drying cycles, reduce risks, and support efficient advancement of sensitive formulations.
-
![GettyImages-1409877704-antibody]( "Early Developability Assessment For Smarter Antibody Selection")
Integrated laboratory and in‑silico developability assessments provide early insight into antibody characteristics, reduce risks, streamline decision‑making, and accelerate progress from discovery toward successful drug product development.
-
![GettyImages-1362084368-particles]( "Beyond Detection: Advanced Strategies For Particle Root-Cause Analysis")
Utilize advanced analytical frameworks and machine learning to rapidly identify contaminants, analyze excipient degradation, and perform root cause investigations to ensure stability and compliance.
